<DOC>
	<DOCNO>NCT00662948</DOCNO>
	<brief_summary>After conventional induction treatment R-CHOP ( Rituximab , cyclophosphamide , adriamycin , vincristine prednisone ) patient randomize : A : Consolidation one dose 90Y Ibritumomab tiuxetan ( Zevalin® ) 0,4 mCi/Kg B : Maintenance 375 mg/m2 Rituximab every 8 week 24 month</brief_summary>
	<brief_title>ZAR2007 : R-CHOP Folicular Lymphoma Patients Treated Previously . Consolidation With 90Y Ibritumomab Tiuxetan ( Zevalin® ) Versus Maintenance Treatment With Rituximab ( MabThera® )</brief_title>
	<detailed_description>The study evaluate benefit consolidation treatment 90Y Ibritumomab tiuxetan ( Zevalin® ) maintenance rituximab ( MabThera® ) term progression free survival , induction chemotherapy rituximab folicular lymphoma patient treat previously . The aim , evaluate global survival , event free survival , time next treatment , response rate consolidation maintenance treatment , quality life , security two branch relation cost-efectivity</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Folicular Lymphoma CD20positive , grade 1 , 2 3a , confirm previous 4 month . Patients treat previously . Ann Arbor Stage II , III IV . Symptoms signes wich indicate necesary treatment ( GELF criterion ) : Ganglionar extraganglionar mass B Symptoms LDH B2microglobuline increase 3 ganglionar territory afected ( &gt; 3 cm ) Esplenomegalia Compresive syndrome Pleural/peritoneal effusion Secondary medular insufiency due infiltration Age &gt; 18 year &lt; 75 year . ECOG &lt; 2 Adecuate hematological function : Hemoglobin &gt; 8,0 g/dl ( 5,0 mmol/L ) ; RAN &gt; 1,5 x 109/L ; platelet &gt; 100 x 109/L No pregnant woman . Women man use appropiate anticonceptive method study one year Informed consent Transformation high grade lymphoma FL grade 3b . Skin gastrointestinal primary lymphoma History CNS diseases ( CNS lymphoma ) Previous treatment Regulary treatment corticosteroid ( permit &lt; 20 mg/day prednisone equivalent ) . Previous cancer disease Major surgery 28 day inclusion study . Creatinine &gt; 2,0 mg/dl ( 197 mmol/L ) Bilirubin &gt; 2,0 mg/dl ( 34 mmol/L ) , AST ( SGOT ) &gt; 3 x upper normal limit . HIV infection active infection VHB VHC &lt; 4 week inclusion . Other complicate disease Criteria investigador : Life expectancy &lt; 6 month . Hipersensibility Ibritumomab tiuxetan , rituximab , murine proteins excipients . Treatment experimental study previous 30 day Any medical psicologycal condition modify capacity give consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Folicular Lymphoma</keyword>
	<keyword>Consolidation</keyword>
	<keyword>Maintenance</keyword>
</DOC>